Mezzion Pharma Co.,Ltd. Company Description

Mezzion Pharma Co.,Ltd. engages in the development, manufacturing, and sale of pharmaceutical products in South Korea.

It is developing udenafil, a PDE5 protein for the treatment of erectile dysfunction, benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, and single heart failure diseases.

The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013.

Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

Mezzion Pharma Co.,Ltd.

Country	South Korea
Founded	2002
Industry	Pharmaceutical Preparations
Employees	17
CEO	Dong-Hyun Park

Contact Details

Address: Seokcheon Building Seoul, 06163 South Korea
Phone	82 2 560 8000
Website	mezzion.co.kr

Stock Details

Ticker Symbol	140410
Exchange	KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2834

Key Executives

Name	Position
Dong-Hyun Park	Chief Executive Officer